Author = Said S Al-Ghora

Helicobacter pylori Infection and Its Impact on Biochemical and Hematological Parameters in Children with Type 1 Diabetes Mellitus

Volume 11, Issue 3, Summer 2026, Pages 929-937

https://doi.org/10.30491/hpr.2026.563223.1527

Mohammed M Laqqan, Said S Al-Ghora, Saleh N Mwafy, Eslam S Alsharif, Maged M Yassin

Abstract Background: Helicobacter pylori (H. pylori) is a prevalent chronic bacterial infection of the gastrointestinal tract, especially in developing regions, yet its extra-gastric consequences in chronic diseases remain insufficiently understood.
Objectives: This case control-study evaluated the influence of H. pylori infection on biochemical and hematological parameters in children with type 1 diabetes (T1D).
Methods: This case–control study enrolled 120 children, including 60 patients with T1DM and 60 apparently healthy, non-diabetic controls, age-matched controls. Participants were recruited from diabetes clinics in 2016. Interviews were completed, and blood samples were analyzed for serum H. pylori IgG using competitive ELISA, alongside various biochemical and hematological measurements.
Results: Children with T1D had lower household income, a stronger family history of diabetes, and higher rates of neuropathy and gastritis than healthy controls (P < 0.05). Significant differences were observed in several biochemical and hematological measures. H. pylori seropositivity was notably more prevalent among children with T1D than among non-diabetic participants (40.0% vs. 21.7%, P = 0.030). Within the diabetic group, infected children demonstrated higher levels of glycated hemoglobin, glucose, insulin, total cholesterol, triglycerides, LDL-C, ALT, and white blood cell counts. In contrast, HDL-C, red blood cell counts, and hemoglobin concentrations were lower in seropositive children. Overall, the findings suggest that H. pylori infection may be associated with poorer glycemic control and greater metabolic and hematological abnormalities in pediatric patients with T1D.
Conclusion: H. pylori infection was associated with unfavorable biochemical and hematological changes in children with TID. Further prospective studies should evaluate whether eradication improves metabolic control.

Serum Vitamin D, Renal Biomarkers, Protein Profile and Some Electrolytes in Chronic Kidney Disease Patients With a Clinical Trial of Vitamin D Therapy

Volume 7, Issue 4, Autumn 2022, Pages 157-163

https://doi.org/10.34172/hpr.2022.30

Maged M. Yassin, Said S. Al-Ghora, Mohammed M. Laqqan, Saleh N. Mwafy, Soha A. Abdallah

Abstract Background: Vitamin D deficiency is involved in a broad spectrum of diseases including chronic kidney disease (CKD).
Objectives: This study was designed to assess serum vitamin D, renal biomarkers, protein profile, and electrolytes in CKD patients with a clinical trial of vitamin D therapy.
Methods: This case-control follow-up interventional study comprised 42 CKD patients and 42 apparently healthy controls. Patients and controls were matched for age and gender. Patients were assigned to receive, a weekly oral dose of vitamin D3 (50000 IU) for 3 successive months. The follow-up therapy was conducted under direct and full physician supervision.
Results: Vitamin D was significantly lower in CKD patients compared to controls (29.6±12.4 versus 35.2±9.9 ng/dL, P=0.033). Significant increases were shown in the urea, creatinine, and uric acid in patients compared to controls whereas glomerular filtration rate (GFR), total protein, albumin, and calcium were significantly lower in patients. A significant improvement was noted for vitamin D and calcium where they registered mean values of 43.8±9.1 ng/dL and 9.65±0.70 mg/dL at the end of the therapeutic period compared to 29.6±12.4 ng/dL and 8.61±0.77 mg/dL in patients before vitamin D therapy (P=0.028 and P=0.033, respectively).
Conclusion: General amelioration of the metabolic profile of CKD patients in response to vitamin D therapy has been shown. Besides a significant improvement in vitamin D and calcium. Consequently, vitamin D is a useful candidate in clinical settings for the improvement of renal function and controlling of CKD, and more importantly its complications.